5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE

5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE

Bibliographic Details
Main Authors:	P. Eleftheriou, J. Sharif, R. Kesse-Adu, M. Filian-Gloor, A. Agrawal, G. Barcelos, P. Telfer
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000928248.83702.ec

Similar Items

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
by: Paul Telfer, et al.
Published: (2018-05-01)

Promising role of voxelotor in managing sickle cell disease in children: a narrative review
by: Amit Agrawal, et al.
Published: (2025-02-01)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
by: Barriteau CM, et al.
Published: (2022-11-01)

Eames house : Charles and Ray Eames /
by: Steele, James, 1943-, 281327
Published: (1994)

Effect of Caffeine on the Polymerization of HbS and Sickling Rate Osmotic Fragility of HbS Erythrocytes
by: A A UWAKWE, et al.
Published: (2004-02-01)

Voxelotor (GBT440) in pediatric sickle cell disease: A review
by: Sri Lakshmi Jamalapur, et al.
Published: (2024-12-01)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
by: Kadère Konté, et al.
Published: (2023-08-01)

Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action
by: Mohd. Suhail
Published: (2024-01-01)

GBT1118, a Voxelotor Analog, Ameliorates Hepatopathy in Sickle Cell Disease
by: Elio Haroun, et al.
Published: (2024-09-01)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
by: Frédéric Galacteros, et al.
Published: (2023-01-01)

Eames House /
by: 437714 Neuhart, Marilyn, et al.
Published: (1994)

S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
by: M Achebe, et al.
Published: (2022-01-01)

Effects of GBT1118, a voxelotor analog, on bone disease in sickle cell disease mice
by: Liping Xiao, et al.
Published: (2024-09-01)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
by: Michael Migotsky, et al.
Published: (2022-09-01)

5610417 IN-VITRO REAL-TIME OBSERVATION OF MODERATE SICKLING KINETICS IN SICKLE ERYTHROCYTES TREATED BY VOXELOTOR UNDER MONOTONIC AND CYCLIC HYPOXIA
by: Y.Q. Qiang, et al.
Published: (2023-04-01)

Changes in indicators of cerebral metabolic stress following treatment with voxelotor in children and adolescents with sickle cell anemia
by: Andrew M. Heitzer, et al.
Published: (2024-10-01)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
by: Radojka M. Savic, et al.
Published: (2022-06-01)

Charles y Ray Eames
by: Esteban Bravo Ovalle
Published: (2003-10-01)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
by: Biree Andemariam, et al.
Published: (2023-08-01)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
by: B. Andemariam, et al.
Published: (2023-04-01)

Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
by: Syeda Tayyaba Rehan, et al.
Published: (2022-07-01)

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
by: Nirmish Shah, et al.
Published: (2023-08-01)

Tool Capability in Visual EAM Analytics
by: Dierk Jugel, et al.
Published: (2015-04-01)

S279: EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY
by: Kadère Konté, et al.
Published: (2023-08-01)

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
by: B. Andemariam, et al.
Published: (2022-06-01)

REAL-WORLD DATA ON THE TREATMENT OF SICKLE CELL DISEASE WITH VOXELOTOR: RESULTS FROM A BRAZIL'S EARLY ACCESS PROGRAM
by: RD Cancado, et al.
Published: (2023-10-01)

Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
by: Awni Alshurafa, et al.
Published: (2022-09-01)

Voxelotor improves red blood cell functionality in children with sickle cell anaemia: An ancillary study of the HOPE‐KIDS 1 trial
by: Satheesh Chonat, et al.
Published: (2024-02-01)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
by: Paul Langley
Published: (2020-05-01)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
by: Michelle L. Green, et al.
Published: (2022-06-01)

Charles Eames and communication : from education to computers
by: Lai, Constance Chunlan, 1972-
Published: (2012)

Charles and Ray Eames : designers of the twentieth century /
by: 210644 Kirkham, Pat
Published: (1995)

Sickle Hyper-hemolytic Transfusion Reaction Syndrome
by: Neha Hurkat
Published: (2018-12-01)

P-013: VOXELOTOR REDUCES SICKLE RED BLOOD CELL-MEDIATED HYPOXIC MICROVASCULAR OCCLUSION AS MEASURED BY OCCLUSIONCHIP IN VITRO MICROFLUIDIC ASSAY
by: SEKYONDA Z., et al.
Published: (2022-08-01)

SiGe bandgap tuning for high speed eam
by: Mastronardi, Lorenzo, et al.
Published: (2019)

Design in Chile What is design?: An interview with Charles Eames
by: Charles Eames
Published: (2001-12-01)

Management Strategy of Implementation of EAM System for Coal Enterprises
by: LI Jian-zhang, et al.
Published: (2012-08-01)

Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease
by: F. Noizat-Pirenne, et al.
Published: (2007-12-01)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
by: C. Minniti, et al.
Published: (2023-04-01)

HbS-Sicilian (δβ)0-Thalassemia: A Rare Variant of Sickle Cell
by: Grace Onimoe, et al.
Published: (2017-01-01)